Cardiac Calcium Channel Blocker Therapy represents a fundamental aspect of cardiovascular care, offering a targeted approach to managing heart-related conditions. These blockers, recognized as calcium antagonists, exert their therapeutic effects by impeding the entry of calcium ions into cardiac muscle cells. This mechanism proves particularly valuable in addressing diverse cardiovascular issues, ranging from hypertension and angina to specific arrhythmias. By facilitating the dilation of blood vessels and promoting cardiac relaxation, calcium channel blockers contribute to improved blood flow and reduced strain on the heart. The incorporation of these medications into a comprehensive treatment strategy underscores their role in optimizing cardiovascular health. It remains imperative for healthcare professionals to personalize prescriptions based on individual patient profiles, ensuring that the therapeutic benefits are maximized while mitigating potential side effects. The dynamic landscape of Cardiac Calcium Channel Blocker Therapy remains a driving force in advancing cardiovascular medicine and elevating the standard of care for individuals with heart-related conditions.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States